Stem cell origin of cancer and differentiation therapy

Critical Reviews in Oncology/Hematology

Volumn 51, Issue 1, 2004, Pages 1-28

  Sell, Stewart ^a  

^a WADSWORTH CENTER   (United States)

Author keywords

Cancer; Carcinogenesis; Differentiation; Differentiation therapy; Embryonal rests; Plasticity; Retinoic acid; Stem cells

Indexed keywords

ANTINEOPLASTIC AGENT; BUCLADESINE; DEXAMETHASONE; INTERLEUKIN 3 RECEPTOR; PACLITAXEL; RETINOIC ACID;

ANAPLASTIC CARCINOMA; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMA CELL; CELL DIFFERENTIATION; CELL DIVISION; CELL LINEAGE; CELL MATURATION; CELL POPULATION; DERIVATIZATION; DISEASE COURSE; EMBRYO CELL; EPITHELIUM CELL; GENE EXPRESSION; GENE MUTATION; GENE TRANSLOCATION; GENETIC VARIABILITY; GERM CELL TUMOR; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; LIVER CARCINOGENESIS; NEPHROBLASTOMA; NERVE CELL PLASTICITY; NEUROBLASTOMA; NONHUMAN; ONCOGENE; ONCOGENE C FOS; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; STEM CELL; STEM CELL TRANSPLANTATION; TERATOCARCINOMA;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; EMBRYONIC DEVELOPMENT; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELLS; HUMANS; MULTIPOTENT STEM CELLS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR STEM CELLS;

EID: 2942691389     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.04.007     Document Type: Review

References (318)

1. Recamier JCA. Recherches dur le Traitement du Cancer, etc. Paris; 1829.
2. Virchow R. Editoral Archiv fuer pathologische Anatomie und Physiologie und fuer klinische Medizin. 8:1855;23
3. Cohnheim J. Ueber entzundung und eiterung. Path Anat Physiol Klin Med. 40:1867;1-79
4. Cohnheim J. Congenitales, quergestreiftes Muskelsarkon der Nireren. Virchows Arch. 65:1875;64
5. Durante F. Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. Arch Memori ed Osservazioni di Chirugia Practica. 11:1874;217-226
6. Sell S., Pierce G.B. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest. 70:1994;6-22
7. Arey LB. Developmental anatomy: a textbook and laboratory manual of embryology. 7th ed. London: WB Saunders Co.; 1974.
8. Sherley J.L. Asymmetric cell kinetics genes: the key to expansion of adult stem cells in culture. Stem Cells. 20:2002;561-572
9. Cairns J. Mutation selection and the natural history of cancer. Nature. 255:1975;197-200
10. Merck J.R., Lansita J.A., James R., Tunstead J.R., Sherley J.L. Cosegregation of chromosomes containing immortal DNA strands in cells that cycle with asymmetric stem cell sinetics. Cancer. Res.62:2002;6791-6795
11. Potten C.S., Owen G., Booth D. Intestional stem cells protect their genome by selective segregation of template DNA strands. J Cell Sci. 115:2002;2381-2388
12. Lin H. To be or not to be. Science. 425:2003;353-355
13. Spradling A., Drummond-Barbosa D., Kai T. Stem cells find their niche. Nature. 414:2001;98-104
14. Xie T, Spradling A. The Drosophila ovary: an in vivo stem cell system. In: Marshak DR, Gardner RL, Gottleib D, editors. Cold Spring Harbor, NY: Cold Spring Harbor Lab. Press; 2001. p. 129-48.
15. Yamashita Y.M., Jones D.L., Fuller M.T. Orientation of asymmetiric stem cell division by the AAPC tumor suppressor and centrosome. Science. 301:2003;1547-1550
16. Lee H-S, Crane G.G., Merok J.R., et al. Clonal expansion of adult rat hepatic stem cell lines by suppression of asymmetric cell kinetics (SACK). Biotechnol Bioeng. 83:2003;760-771
17. Wodarz A., Nusse E. Mechanksms of Wnt signaling in develompent. Annu Rev Cell Dev Biol. 14:1998;59-88
18. Taipale J., Beachy P.A. The hedgehog and Wnt signaling pathways in cancer. Nautre. 411:2002;349-354
19. Nakano T. Hematopoietic stem cells; generation and manipulation. Trends Immunol. 24:2003;589-594
20. Pesche M., Gross M.K., Scholer H.R. In line with out ancestors: Oct-4 and the mammalian germ. BioEssays. 20:1998;722-732
21. Brehm A., Ohbo K., Zwerschke W., Botquin V., Jansen-Durr P., Scholer H.R. Synergism with germ line transcription factor OCT-4: viral oncoproteins share the ability to mimic a stem cell acrivity. Mol Cell Biol. 19:1999;2635-2643
22. Oliver R.T. Germ cell cancer. Curr Opin Oncol. 11:1999;236-241
23. Pera M.F., Herszfeld D. Differentiation of human pluripotent teratocarcinoma stem cells induced by bone morphogenic protein-2. Reprod Fertil Dev. 10:1998;551-555
24. Kraft H.J., Mosselman S., Smits H.A., Hohenstein P., Piek E., chen Q., Artzt K., van Zoelen E.J. Oct-4 regulates alternative platelet-derived growth factor alpha receptor gene promoter in human embryonal carcinoma cells. J Biol Chem. 271:1996;12873-12878
25. Polakis P. Wnt signaling and cancer. Genes Dev. 14:2000;1837-1851
26. Peifer M., Plakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science. 287:2000;1606-1609
27. Shibata R., Chuma M., Kokubu A., Sakamoto M., Hirohashi S. EBP50, a beta-catenin-associating protein, enhances WNT signaling and is over-expressed in hepatocelluar carcinomas. Hepatology. 38:2003;178-186
28. Ueda M., Higikata M., Takagi S., Takada R., Takada S., Chiba T., Shimotohno K. Wnt/beta-catenin signaling suppresses apoptosis in low serum medium and induces morphologic change in rodent fibroblasts. Int J Cancer. 99:2002;681-688
29. Chen S., Guttridge D.C., You Z., Zhang Z., Fribley A., Mayo M.W., Kitajewski J., Wang C.Y. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol. 152:2001;87-96
30. Gat U, Das Gupta R, Degenstein L, Fuchs E. De novo hair follicle morphogeneisis ahd hair tumors in mice expressing a truncated β-catenin in skin. Cell 1998:605-14.
31. Vainio S., Heikkila M., Kispert A., Chin N. McMahon. Female development in mammals is regulated by Wnt-4 signalling. Nature. 397:1999;405-409
32. Saddi-Kheddouci S., Berrebi D., Romagnolo B., Cluzeaud F., Peuchmaur M., Kahn A., Vandewalle A., Perret C. Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene. Oncogene. 20:2001;5972-5981
33. Vonica A., Gumbiner B.M. Zygotic Wnt activity is required for Brachyury expression in the early Xenopus laevis embryo. Dev Biol. 250:2002;112-127
34. Coyle-Rink J., Del Balle L., Sweet T., Khalili K. Amini s. Developmental expression of Wnt signaling factors in mouse brain. Cancer Biol Ther. 1:2002;640-645
35. Serrano N, O'Farrel PH. Limb morphogenesis: connections between patterning and growth. Curr Biol 1997:R186-95.
36. Ivanova N.B., Dimos J.T., Schaniel C., Hackney J.A., Moore K.A., Lemischka I.R. A stem cell molecular signature. Science. 298:2002;601-604
37. Nusse R., Varmus H. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 31:1982;99-109
38. Shimizu H., Julius M.A., Giarre M., Zheng Z., Brown A.M., Kitajewski J. Transformation by Wnt family proteins correlates with regulation of beta-catenin. Cell Growth Diff. 8:1997;1349-1358
39. Hirohashi S., Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci. 94:2003;575-581
40. Imbert A., Eelkema R., Jordan S., Feiner H., Cowin P. ΔN89 β-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol. 153:2001;555-568
41. Shutman M., Zhurinsky J., Simcha I., et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci USA. 96:1999;5522-5527
42. Behrens J. Cadherins and catenins: role of in signal transduction and tumor progression. Cancer Met Rev. 18:1999;15-30
43. He T.C., Sparks A.B., Rago C., et al. Identification of c-myc as a target of the APC pathway. Science. 281:1999;1509-1512
44. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170
45. Cong F., Zhang J., Pao W., Ahou P., Varmus H. A protein knockdown strategy to study the function of β-catenin in tumorigenesis. BMC Mol Biol. 4:2003;10-20
46. Katoh M. Wnt2 and human gastrointestinal cancer. Int J Mol Med. 12:2003;811-816
47. Kock A., Denkhaus D., Albrecht S., Leuschner I., et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the β-catenin gene. Cancer Res. 59:1999;269-273
48. De La Coste A., Romagnolo B., Billuart P., Renard C.A., et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl Acad Sci U.S.A. 95:1998;8847-8851
49. Ban K.C., Singh H., Krishnan R., Seow H.F. GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma. Cancer Lett. 199:2003;201-208
50. Huang H., Ushijima T., Nagao M., Sugimura T., Ohgaki H. Beta-catenin mutations in liver tumors induced by 2-amino-3, 4-dimethylimidazo[4, 5-f]quinoline in CDF1 mice. Cancer Lett. 198:2003;29-35
51. Anna C.H., Iida M., Sills R.C., Devereux T.R. Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice. Toxicol Appl Pharmoacol. 190:2003;135-145
52. Rice P.L., Kelloff J., Sullivan H. Sulindac motabolites induce capase- and proteasome-dependent degradation of β-catenin protein in human colon cancer cells. Mol Cancer Ther. 2:2003;885-892
53. Li H., Pamukeu R., Thompson W.J. Beta-Catenin signaling: therapeutic strategies in oncology. Cancer Biol Ther. 1:2002;621-625
54. Lim J.T., Piazza G.A., Pamuku R., Thompson W.J., Weinstein I.B. Exisulind and related compounds inhibit expression and function of the andraogen receptor in human prostate cancer cells. Clin Cancer Res. 9:2003;4972-4982
55. Pusztai L., Shen J.H., Arun B., et al. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol. 21:2003;3454-3461
56. Martin G. Teratocarcinomas and mammalian embryogenesis. Science. 209:1980;768-776
57. Herzog E.L., Chai L., Krause D.S. Plasticity of marrow-derived stem cells. Blood. 102:2003;3483-3493
58. Garder R.L. Extrinsic factors in cellular differentiation. Int J Dev Biol. 37:1993;47-50
59. Wuff G.G., Jackson K.A., Goodell M.A. Somatic stem cell plasticity: current evidence and emerging concepts. Exp. Hematol. 29:2001;1361-1370
60. Prockop D.J. Marrow stromal cells as stem cells for non-hematopoietic tissues. Science. 276:1997;71-74
61. Minguell J.J., Erices A., Conget P. Mesenchymal stem cells. Exp Biol Med. 226:2001;506-520
62. Korbling M., Estrov Z. Adult stem cells for tissue repair - a new therapeutic concept. N Eng J Med. 349:2003;570-582
63. Liang L., Bickenbach J.R. Somatic epidermal stem cells can produce multiple cell lineages during development. Stem Cells. 20:2002;21-31
64. Virchow R. Die krankhafter Geschwulste. Bd 1. Berlin: Hirschwald; 1863.
65. Cohnhein J. Lectures in general pathology. London: The New Sydenham Society; 1889 [translated from the second German edition by McKee AB].
66. Oberling C. The riddle of cancer. New Haven: Yale University Press; 1944.
67. RippertV. Ueber ein myosarcoma striocellulare des nierenbeckens und des ureters. Bonn: Geschwulstlehre; 1904; Bonn: Das carcinom des menschen; 1911.
68. Rotter W. Histogenese der malignen Geschwulste. Ztschr Krebsforschung. 18:1921;171-208
69. Paget S. The distribution of secondary growth in cancer of the breast. Lancet. 1:1889;571-573
70. Fidler I.F. Tumor heterogeneity and the biology of cancer invasion and growth. Cancer Res. 38:1978;2651-2666
71. Boveri T. The origin of malignant tumors. Baltimore: Williams and Wilkins Co.; 1929 [English translation by Marcella Boveri].
72. Frank S.A., Nowak M.A. Developmental predisposition to cancer. Nature. 422:2003;494
73. Pierce GB, Shikes R, Fink LM. Cancer: a problem of developmental biology. Englewood Cliffs, NJ: Prentice-Hall Inc.; 1978. 242pp.
74. Wilms M. Die Mischgeschwuelste. Leipzing: Arthur Georgi; 1899.
75. Ladd W.E., White R.R. Embryoma of the kidney (Wilms' tumor). JAMA. 117:1941;1858-1863
76. Fraser J. Adeno-sarcomatous tumors of the kidney: a clonco-pathological study. Edinburgh Med. J. 24:1920;372-391
77. Beckwith J.B., Palmer N.F. Histopathology and prognosis of Wilm's tumor: results from the first national Wilm's tumor study. Cancer. 41:1978;1937-1948
78. Kretschmer H.L. Malignant tumors of the kidney in children. J Urology. 39:1938;250-275
79. Wright J.H. Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J Exp Med. 12:1910;556-563
80. Shimada H., Chatten J., Newton W.A., et al. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. JNCI. 73:1984;405-416
81. Stevens L.C. Experimental production of testicular teratoma in mice. J Natl Cancer Inst. 52:1967;549-552
82. Stevens L.C. The development of transplantable teratocarcinomas from intratesticular grafts of pre- and post-implantation of mouse embryos. Dev Biol. 21:1970;364-382
83. O'Hare M.J. Teratomas, neoplasia and differentiation: a biological overview I, The natural history of teratomas. Invest Cell Pahotol. 1:1978;39-63
84. Pierce G.B., Dixon F.J. Testicular teratomas. Part I. Demonstration of teratogenesis by metamorphosis of multipotential cells. Cancer. 12:1959;573-583
85. Pierce G.B., Dixon F.J., Verney I.L. Teratocarcinogenic and tissue forming potentials of the cell types comprising neoplastic embryoid bodies. Lab Invest. 9:1960;583-602
86. Kleinsmith L.J., Pierce G.B. Multipotentiality of single embryonal carcinoma cells. Cancer Res. 24:1964;1544-1551
87. Peyron A. Sur la presence des cellules genitales primordiales dans les boutons embryonnaires des embryomes parthenogenetiques chez l'homme. C. R. Acad Sci (Paris). 206:1938;1680-16831
88. Pierce G.B., Varney El. An in vitro and in vivo study of differentiation in teratocarcinomas. Cancer. 14:1961;1017-1029
89. Pierce G.B., Wallace C. Differentiation of malignant to benign cells. Cancer Res. 31:1971;127-134
90. Thurlbeck W.M., Scully R.E. Solid teratoma of the ovary: a clinico-pathological analysis of 9 cases. Cancer. 13:1960;804-811
91. Brinster R.E. The effect of cells transferred into the mouse blastocyst on subsequent development. J Exp Med. 140:1874;1049-1056
92. Mintz B., Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA. 72:1975;3583-3589
93. Papaionnou V.E., McBurney M.W., Gardner R.L., Evans R.L. Fate of teratocarcioma cells injected into early mouse embryos. Nature. 258:1975;70-73
94. Potter VR. Mechanisms of carcinogenesis in relation to studies on minimal deviation hepatomas. Exploitable molecular mechanisms and neoplasia. Texas Press; 1968. p. 587.
95. Potter V.R. Phenotypic diversity in experimental hepatomas: the concept of partially blocked ontogeny. Br J Cancer. 38:1978;1-23
96. Gurdon J.B., Bourillot P.-Y. Morphogen gradient interpretation. Nature. 413:2001;797-803
97. Evans MJ, Kaufman MY. Establishment in culture of pluripotential cells from mouse embryos. Nature 292:154-6.
98. Bradley A., Evans M., Kaufman M.H., Robertson E. Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature. 309:1984;255-256
99. Robertson E.J. Pluripotential stem cells lines as a route into the mouse germ line. Trends Genet. 2:1986;9-14
100. Papaioannou V.E. Ontogeny, pathology, oncology. Int. J. Dev. Biol. 37:1993;33-37
101. Papaioannou V.E., Rossant J. Effects of the embryonic environment on proliferation and differentiation of embryonal carcinoma cells. Cancer Suv. 2:1983;165-183
102. Gardner R.L. Mouse chimaeras obtained by the injection of cells into the blastocyst. Nature. 220:1969;596-597
103. Slack C., Morgan R.H.M., Hooper M.L. Isolation of metabolic cooperation-defective variants from mouse embryonal carcinoma cells. Exp Cell Res. 117:1978;195-205
104. Gootwine E., Webb C.G., Sachs L. Participation of myeloid leukaemia cells injected into embryos in hematopoietic differentiation in adult mice. Nature. 299:1982;63-65
105. Podesta A.N., Mulllins J., Pierce G.B., Sells R.S. The neurula state mouse embryos in control of neuroblastomas. Proc Natl Acad Sci USA. 81:1984;7608-7611
106. Gerschenson M., Graves K., Carson S.D., Wells R.S., Pierce G.B. Regulation of melanoma by the embryonic skin. Proc Natl Acad Sci USA. 83:1986;7303-7310
107. Gramzinski R.A., Parchments R.E., Pierce G.B. Evidence linking programmed cell death in the blastocyst to polyamine oxidation. Differentiation. 43:1990;59-65
108. Pierce G.B., Parchment R.E., Lewellyn A. Hydrogen peroxide as a mediation of programmed cell death in the blastocyst. Differentiation. 46:1991;181-186
109. Parchment R.E., Pierce G.B. Polyamine oxidation, programmed cell death, and regulation of melanoma in the murine embryonic limb. Cancer Res. 49:1989;6680-6686
110. Biava P.M., Bonsignorio D. Cancer and cell differentiation: a model to explain malignancy. J Tumor Marker Oncol. 17:2002;47-53
111. Biava P.M., Bonsignorio D., Hosha M., et al. Mother-embryo cross-talk: the anti-cancer substances produced by mother and embryo during cell differentiation. A review of experimental data. J Tumor Marker Oncol. 17:2002a;55-58
112. Biava P.M., Bonsignorio D., Hosha M. Cell proliferation curves of different human tumor lines after in vitro treatment with Zebrafish embryonic extracts. J Tumor Marker Oncol. 16:2001;195-201
113. Perez-Losada J., Balmain A. Stem cell hierarchy in skin cancer. Nat. Rev. Cancer. 3:2003;434-443
114. Owens D.M., Watt F.M. Contribution of stem cells and differentiated cells to epidermal tumors. Nat. Rev. Cancer. 3:2003;444-451
115. Brown K., Strathdee D., Bryson S., Lambie W., Balmain A. The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted. Curr Biol. 8:1998;514-516
116. Waikel R.L., Kawachi Y., Waikel P.A., Wang X.J., Roop D.R. Deregulated expression of c-Myc depletes epidermal stem cells. Nat. Genet. 28:2001;165-168
117. Arnold I., Watt F.M. c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol. 1:2001;558-568
118. Pelengaris S., Littlewood T., Khan M., Elia G., Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mole Cell. 3:1999;565-577
119. Munger K., Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res. 89:2002;213-238
120. Garland A.M. Human papillomavirus update with a particular focus on cervical disease. Pathology. 34:2002;213-224
121. Rous P., Kidd J.G. Conditional neoplasms and subthreshold neoplastic states. J Exp Med. 73:1942;365-372
122. Friedwald W.F., Rous P. The initiating and promoting elements in tumor production. An analysis of the effects of tar, benzpyrene and methylcholanthrere on rabbit skin. J Exp Med. 80:1944;101-126
123. Berenblum I., Shubik P. A new quantitative approach to the study of the stages of chemical carcinogenesis in the mouse's skin. Brit J Cancer. 1:1947;384-391
124. Beremblum I. Carcinogenesis and tumor pathogenesis. Adv Cancer Res. 2:1954;129-175
125. Boutwell R.K. Some biological aspects of skin carcinogenesis. Progr Exp Tumor Res. 4:1964;207-250
126. Van Duuren B.L., Sivak A., Katz C., Seidman I., Melchionne S. The effect of ageing and interval between primary and secondary treatment in two-stage carcinogenesis on mouse skin. Cancer Res. 35:1975;502-505
127. Potten C.S., Morris R.J. Epithelial stem cells in vivo. J Cell Sci. 10(Suppl 1):1988;45-62
128. Watt F.M. Terminal differentiation of epidermal keratinocytes. Curr Opin Cell Biol. 1:1989;1107-1115
129. Slaughter D.P., Southwick H.W., Smejdal W. "Field cancerization" in oral stratified squamous epithelilum. Cancer. 6:1953;963-968
130. Carlson J.A., Scott D., Wharton J., Sell S. Incidental histopathologic patterns: possible evidence of "Field Cancerization" surround skin tumors. Am J Dermatopath. 23:2001;494-497
131. Braakhuis B.J.M., Tabot M.P., Kummer J.A., Leemans C.R., Brakenhoff R.H. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 63:2003;1727-1730
132. Dunsford H.A., Karnasuta C., Hunt J.M., Sell S. Different lineages of chemically induced hepatocellular carcinoma in rats defined by monoclonal antibodies. Cancer Res. 49:1989;4898-4900
133. Sell S. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology. 33:2001;738-750
134. Higgins G.M., Anderson R.M. Experimental pathology of the liver, Restoration of the liver of the white rat following partial surgical removal. AMA Arch Pathol. 12:1931;186-202
135. Grisham J.W. A morphologic study of deoxyribonucleic acid synthesis and cell proliferation in regenerating rat liver; autoradiography with thymidine-H3. Cancer Res. 22:1962;842-849
136. Bucher NLR, Malt RA. Regeneration of the liver and kidney. Boston: Little. Brown and Co; 1971.
137. Yoshida T. o-Amidoazotoluol; uber die expermentelle annulare Lebercirrhose des Kaninchens. Jpn Path Soc. 25:1935;409-411
138. Kinosita R. Special report: studies on the cancerogenic chemical substances. Tr Jpn Path Soc. 27:1937;665-725
139. Opie E.L. The pathogenesis of tumors of the liver produced by butter yellow. J Exp Med. 80:1944;231-246
140. Orr E.L. The histology of the rat's liver during the course of carcinogenesis by butter-yellow (p-dimethylaminoazobenzene). J Path Bact. 50:1940;393-408
141. Farber E. Similarities in the sequence of early histologic changes induced in the liver by ethionine, 2-acetylamionfluorene and 3′-methl-4-dimethylaminoazobenzene. Cancer Res. 16:1956;142-148
142. Farber E. Precancerous steps in carcinogenesis: their physiological adaptive nature. Biochim Biophus Acta. 738:1984;171-180
143. Teebor G.E., Becker F.F. Regression and persistence of hyperplastic hepatic nodules induced by N-2-fluorenylacetatamide and their relationship to hepatocarcinogenesis. Cancer Res. 31:1971;1-2
144. Grisham J.W., Porta E.A. Origin and fate of proliferated hepatic ductal cells in the rat: electron microscopic and autoradiographic studies. Exp Mole Pathol. 3:1964;242-261
145. Watabe H. Early appearance of embryonic alpha-globulin in rat serum during carcinogenesis with 4-dimethylaminoazobenzene. Cancer Res. 31:1971;1192-1194
146. Sell S., Becker F.F. Alphafetoprotein. J Natl Cancer Inst. 60:1978;19-26
147. Becker F.F., Sell S. Differences in serum alpha-fetoprotein concentrations during the carcinogenic sequences resulting from exposure to dethynitorsamine of acetyaminofluorene. Cancer Res. 39:1979;1437-1442
148. Stillman D., Sell S. Models of chemical hepatocarcinogenesis and oncodevelopmental gene expression. Meth. Cancer Res. 18:1979;135-168
149. Sell S., Osborn K., Leffert H.L. Autoradiography of "oval cells" appearing early in the livers of rats fed N-2-fluorenyacetamide in a choline devoid diet. Carcinogenesis. 2:1981;7-14
150. Sell S., Salman J. Light and electromicroscopic autoradiographic analysis of proliferating cells during the early stages of chemical hepatocarcinogenesis in the rat induced by feeding N-2-fluorenylacetamide in a choline deficient diet. Am J Pathol. 114:1984;287-300
151. Sell S., Leffert H.L. An evaluation of cellular lineages in the pathogenesis of experimental hepatocellular carcinoma. Hepatology. 2:1982;77-86
152. Novikoff P.M., Ikeda T., Hixson D.C., Yam A. Characterizations of and interactions between bile ductule cells and hepatocytes in early stages of rat hepatocarcinogenesis induced by ethionine. Am J Pathol. 139:1991;1351-1368
153. Lenzi R., Liw M.H., Ratsetti F., et al. Histogenesis of bile duct-like cells proliferating during ethionine hepatocarcinogenesis. 66:1992;390-402
154. Solt D.B., Medline A., Farber E. Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis. Am J Pathol. 88:1977;595-609
155. Everts R.P., Nagy P., Nakatsukasa H., Marsden E., Thorgeirsson S.S. In vivo differentiation of rat liver oval cells into hepatocytes. Cancer Res. 49:1989;1541-1547
156. Novikoff P.M., Yam A., Oikawa I. Blast line cell compartment in carcinogen-induced proliferating bile ductules. Am J Pathol. 148:1996;1473-1492
157. Alison M.R., Golding M.H.C., Sarraf C.E. Pluripotential liver stem cells: facultative stem cells located in the biliary tree. Cell Prolif. 29:1996;373-402
158. Alison MR, Poulsom R, Jerrery R, et al. Hepatocytes form non-hepatic adult stem cells. Nature 2000;405:257.
159. Bisgaard H.C., Nagy P., Santoni-Rugiu E., Thorgeirsson S.S. Proliferation apoptosis, and induction of hepatic transcription factors are characteristics of the early response of biliary epithelial (oval) cells to chemical carcinogens. Hepatol. 23:1996;62-70
160. Yavorkovsky L., Lai E., Sell S. Participation of small intraportal "stem" cells in the restitutive response of the liver to periportal necrosis induced by allyl alcohol. Hepatology. 21:1995;1702-1712
161. Petersen B.E., Bowen W.C., Patrene K.D., et al. Bone marrow as a potential source of hepatic of hepatic oval cells. Science. 284:1999;1168-1170
162. Theise N.D., Badve S., Saxena R., et al. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology. 31:2000;235-240
163. Krause D.S., Theise N.D., Collector M.I., et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 105:2001;369-377
164. Lagasse E., Conners H., Al-Shalimy M., et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 6:2000;1229-1234
165. Wang X., Willenbring H., Akkari Y., et al. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature. 422:2003;897-901
166. Vassilopoulos G., Wang P.-R., Russell D.W. Transplanted bone marrow regenerates liver by cell fusion. Nature. 422:2003;901-904
167. Newsome PN, Johannessen I, Boyle S, et al. Human cord blood-derived cells can differentiate into hepatocytes in the mouse liver with no evidence of fusion. Gastroenterology 2003;124:1891-900.
168. Ishikawa F., Drake C.J., Yang S., et al. Transplanted human cord blood cells give rise to hepatocytes in engrafted mice. Ann NY Acad Sci. 996:2003;174-185
169. Alvarez-Dolando N.A., Pardal R., Garcia-Verdungo J.M., et al. Fusion of bone marrow-derived cells with Purkinje neurons, cardioinmyocytes and hepatocytes. Nature. 425:2003;968-973
170. Ianus A., Holz G.G., Theise N.D., Hussain M.A. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow with no evidence of cell fusion. J. Clin Invest. 111:2003;843-850
171. Wellings S.R., Jensen H.M., Marcum R.G. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst. 55:1975;231-273
172. Haslan S.Z., Bern H.A. Histopathogenesis of 7, 12-dimethylbenz[a] anathracene-induced rat mammary tumors. Proc Natl Acad Aci USA. 74:1977;4020-4024
173. Medina D. The preneoplastic state in mouse mammary tumorigenesis. Carcinogenesis. 9:1988;113-119
174. Bonkhoff H., Remberger K. Differentiation pathways and histogenietic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate. 28:1996;98-106
175. Kadkol S.S., Brody J.R., Epstein J.I., Kuhajda F.P., Pasternack G.R. Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer. Prostate. 34:1998;231-237
176. Dubey P., Wu H., Reiter R.E., Witte O.N. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Cancer Res. 61:2001;3256-3261
177. Kim X.H., Roth K.A., Moser A.R., Gordon J.I. Transgenic mouse models that explore the multistep hypothesis on intestinal neoplasia. J Cell Biol. 123:1993;877-893
178. Garcia S.B., Park H.Y., Novelli M., Wright N.A. Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. J Pathol. 187:1999;61-81
179. Zhang T., Otevrel T., Gao Z., et al. Evidence that APC regulates survivin expression, a possible mechanism contribution to the stem cell origin of colon cancer. Cancer Res. 62:2001;8664-8667
180. Thompson L, Chang B, Barsky SH. Monoclonal origins of malignant mixed tumors (Carcinosarcomas). Am J Surg Pathol 1996;20:277-85.
181. Reya T., Morrison S.J., Clake M.F., Weissman I.L. Stem cells, cancer and cancer stem cells. Nature. 414:2001;105-111
182. Pappenheim A. Prinzipien der neueren morphologischen Haematozytologie nach zytogenetischer Grundlage. Folia haematol. 21:1917;91-101
183. Till J.E., McCulloch E.A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 14:1961;213-222
184. Siminovich L., McCulloch E.A., Till J.E. The distribution of colony-forming cells among spleen colonies. J Cell Comp Physiol. 62:1963;327-336
185. Carnie AM, Lala PK, Osmond DG, editors. Stem cells of renewing cell populations. New York: Academic Press; 1976.
186. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and function properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 183:1996;1797-1806
187. Weatherall D.J. ABC of clinical haematology. The hereditary anaemias. Brit Med J. 314:1997;492-498
188. Graf T. Differentiation plasticity of hematopoietic cells. Blood. 99:2002;3089-3101
189. Choi K. Hemangioblast development and regulation. Biochem Cell Biol. 76:1998;947-956
190. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 85:1999;221-228
191. Rifai S., Lyden D. therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nature Med. 9:2003;702-712
192. Bailey A.S., Jiang S., Afentoulis M., et al. Transplanted adult hematopoietic stem cells differentiate into functional endothelial cells. Blood. 103:2004;13-19
193. Ferrari G., Cusella-DeAngelis G., Coletta M., et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science. 279:1998;1528-1530
194. Ng I.-L, Chang K.-L, Sheck W.-H., et al. High frequency of chimerism in transplanted livers. Hepatology. 38:2003;989-998
195. Lee V.M., Stoffel M. Bone marrow: an extra-pancreatic hideout for the elusive pancreatic stem cell? J Clin Invest. 111:2003;799-801
196. Hess D., Li L., Martin M., et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nature Biotechnol. 21:2003;763-770
197. Jackson K.A., Majka S.M., Wang H., et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest. 107:2001;1395-1402
198. Quaini F., Urbanek K., Beltrami A.P., et al. Chimerisms of the transplanted heart. N. Engl J. Med. 346:2002;5-15
199. Li Y., Chen J., Wang L., Lu M., Chopp M. Treatment of stroke in rat with intracarotid administration of marrow stromal cells. Neurology. 56:2001;1666-1672
200. Eglitis M.A., Mezey E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci. 94:1999;4080-4085
201. Priller J., Persons D.A., Klett F.F., Kempermann G., Kreutzberg G.W., Dirnagl U. Neogenesis of cerebellar Purkinje neurons form gene-marked bone marrow cells in vivo. J. Cell Biology. 155:2001;733-738
202. Mansergh F.C., Wride M.A., Rancourt D.E. Neurons from stem cells implications for understanding nervous system development and repair. Biochem Cell Biol. 78:2000;613-628
203. Zhao L.R., Duan W.M., Reyes M., Keene C.D., Verfaillie C.M., Low W.C. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol. 174:2002;11-20
204. Kotten D.N., Ma B.Y., Cardoso W.V., et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development. 128:2001;5181-5188
205. Poulsom R., Forbes S.J., Hodivala-Dilke K., et al. Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol. 195:2001;229-235
206. Kataoka K., Medina R.J., Kageyama T., et al. Participation of adult mouse bone marrow cells in reconstitution of skin. Am. J Pathol. 163:2003;1227-1231
207. Tomita M., Adachi Y., Yamada H., et al. Bone marrow-derived stem cells can differentiate into retinal cells in injured rat retina. Stem Cells. 20:2002;279-283
208. Bookmaaker M.B., Smits A.M., Tolboon H., et al. Bone marrow-derived cells contribute to glomerular endothelial repair in experimental glomerulonephritis. Am J Pathol. 163:2003;553-562
209. Forbes S.J., Poulsom R., Wright N.A. Hepatic and renal differentiation from blood-borne stem cells. Gene Therapy. 9:2002;625-630
210. Masuya M., Drake C.J., Fleming P.A., et al. Hematopoietic origin of glomerular mesangila cells. Blood. 101:2003;2215-2218
211. Pittenger M.F., McKay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science. 284:1999;143-147
212. Donovan P.J., Gearhart J. The end of the beginning for pluripotent stem cells. Nature. 414:2001;92-97
213. Prockop D.J., Gregory C.A., Spees J.L. One strategy for cell and gene therapy: Harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci USA. 100(Suppl 1):2003;11917-11923
214. Labat M.L. Stem cell and the promise of eternal youth: embryonic versus adult stem cells. Biomed Pharmacother. 55:2001;179-185
215. Gunsilius E., Gastl G., Petzer A.L. Hematopoietic stem cells. Biomed Pharmocother. 55:2001;186-194
216. Jiang Y., Jahagirdar B.N., Reinhardt R.L., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 418:2002;41-49
217. Hillebrands J.L., Klatter F.A., van Dijk W.D., Rozing J. Bone marrow does not contribute substantially to endothelial-cell replacement in transplant arteriosclerosis. Nat Med. 8:2002;194-195
218. McKinney-Freeman S.L., Jackson K.A., Camargo F.D., Ferrari G., Mavilio F., Goodell M.A. Muscle-derived hematopoietic stem cells are hematopoietic in origin. Proc Natl Acad Sci USA. 299:2003;1341-1346
219. Bjornson C.R.R., Rietz Rl, Reynolds B.A., Magli M.C., Vesonvi A.L. Turning brain into blood: a hematopoietic fate adopted by adult nerual stem cells in vivo. Science. 183:1999;534-537
220. Morshead C.M., Benveniste P., Iscove N.N., van der Kooy D. Hematopoietic competence is a rare properety of neural stem cells that may depend on genetic and epigenetic alterations. Nat. Med. 2:2002;268-273
221. Terada N., Hamazaki T., Oka M., et al. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature. 416:2002;542-545
222. Ying Q.-L., Nichols J., Evans E.P., Smith A.G. Changing potency by spontaneous fusion. Nature. 416:2002;541-548
223. Tran S.D., Pillemer S.R., Dutra A., et al. Differentiation of human bone marrow-derived cells into buccal epithelial cell in vivo; a molecular analytical study. The Lancer. 361:2003;1084-1088
224. Theise N.D., Wilmut I. Flexible rearrangement. Nature. 425:2003;21
225. Wagers A.J., Sherwood R.I., Christensen J.L., Weissman I.L. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science. 297:2002;2256-2262
226. Doyonnas R, Blau HM. What is the future for stem cell research: whether entity or function? In: Sell S, editor. Stem cells handbook. Totowa, NJ: Humana Press; 2003. p. 491-9.
227. Blau H.M., Brazelton T.R., Weimann J.M. The evolving concept of a stem cell: entity or function? Cell. 105:2001;829-841
228. Bartlett P.F. Pluripotential hemopoietic stem cells in the adult mouse brain. PNAS. 79:1982;2722-2725
229. Passeque E., Jamieson D.H., Ailles L.I., Weissman I.L. Normal and leukemice hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell properties. Procnatl Acad Sci USA. 100(Suppl 1):2003;11842-11849
230. Furth J., Kahn M.C. The transmission of leukemia of mice with a single cell. Am J Cancer. 31:1937;276-282
231. Makino S., Kano K. Cytological studies of tumors, XIV. Isolation of single-cell clones from a mixed-cell tumor of the rat. JNCI. 15:1955;1165-1181
232. Rowley J.D. The role of chromosomal translocations in leukemogenesis. Semin. Hematol. 36:1999;59-72
233. Schmidt C.A., Przybylski G.K. Want we can learn from leukemia as for the process of lineage commitment in hematopoiesis? Int Rev Immunol. 20:2001;107-115
234. Pardal R., Clarke M.F., Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer. 3:2003;895-902
235. Baird SM. Hematopoietic stem cells in leukemia and lymphoma. In: Sell S, editor. Stem cells handbook. Totowa, NY: Humana Press; 2003. p. 163-75.
236. Sen F., Vega F., Mederios L.J. Molecular genetic methods in the diagnosis of hematologic neoplasms. Semin Diagn Pathol. 19:2003;973-984
237. Gleissner B., Theil E. Molecular genetic events in adult acute lymphoblastic leukemia. Expert Rev Mol Diagn. 3:2003;339-355
238. Cory S., Vaux D.L., Strasser A., Harris A.W., Adams J.M. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res. 59:1999;1686s-1692s
239. Campo E. Genetic and molecular genetic studies in the diagnosis of B-cell lymphomas I. mantle cell lymphoma, follicular lymphoma and Burkitt's lymphoma. Hum Pathol. 34:2003;330-335
240. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:1997;730-737
241. Dontu G., Al-Hajj M., Abdallah W.M., Clarke M.F., Wicha M.S. Stem cells in normal breast development and breast cancer. Cell Prolif. 36(Suppl 1):2003;59-72
242. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:2003;5821-5828
243. Pierce G.B. The cancer cell and its control by the embryo. Am J Pathol. 113:1983;117-124
244. Spira A.I., Carducci M.A. Differentiation therapy. Curr Opin Pharmacol. 3:2003;338-343
245. Strickland S., Madavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell. 15:1978;393
246. Strickland S., Smith K.K., Morotti K.R. Hormonal induction of differentiation in teratocarcinoma stem cells: generation of parietal endoderm by retinoic acid and dibutyryl cAMP. Cell. 21:1980;347-355
247. Grover A., Adamson E.D. Evidence for the existence of an early common biochemical pathway in the differentiation of F9 cells into visceral or parietal endoderm: modulation by cyclic AMP. Dev Biol. 114:1986;492-503
248. Wasylyk B., Imler J.L., Chatton B., Schatz C., Wasylyk C. Negative and positive factors determine the activity of the polyoma virus enhancer alpha domain in undifferentiated and differentiated cell types. Proc Natl Acad Sci. 85:1988;7952-7956
249. Oshima R.G., Abrams L., Kulesh D. Activation of an intron enhancer within the keratin 18 gene by expression of c-fos and c-jun in undifferentiated F9 embryonal carcinoma cells. Genes Dev. 4:1990;848-853
250. Boylan J.F., Lufkin T., Achkar C.C., Taneja R., Chambon P., Gudas L.J. Targeted disruption of retinoic acid receptor α (RARα) and RARγ results in receptor-mediated alterations in retinoic acid-mediated differentiation and retinoic acid metabolism. Mol Cell Biol. 15:1995;843-851
251. Choi S.K., Yeh J-C, Cho M., Cummings R.D. Transcription regulation of 1, 3-galactosyltransferase in embryonal carcinoma cells by retinoic acid. J Biol Chem. 271:1996;3238-3246
252. Congyi C., Gudas L.J. Murine laminin B1 gene regulation during the retinoic acid- and dibutyryl cycic AMP-induced differentiation of embryonic stem cells. J Biol Chem. 271:1996;6810-6818
253. Chen H., Dong J.M., Liu Y., Chiu J.F. Identification of a cis-acting element in the rat alphafetoprotein gene and its specific binding proteins in F9 cells during retinoic acid-induced differentiation. J Cell Biochem. 72:1999;25-34
254. Sun S.Y., Yue P., Mao L. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res. 6:2000;1563-1573
255. Mehta K. Retinoids as regulators of gene transcription. J Biol Regul Homeost Agents. 17:2003;1-12
256. Sun S.Y., Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol. 41:2002;41-55
257. Smith E.R., Capo-chichi C.D., He J., et al. Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinoic acid in embryonic carcinoma cells. J Biol Chem. 276:2001;47303-47310
258. Malashicheva A.B., Kisliakova T.V., Pospelov V.A. G1 block of the cell cycle during differentiation of F9 cells correlates with accumulation of inhibitors of the activity of cyclin-kinase complexes of proteins p21/Waf1 and p26/Kip. Tsitologiia. 44:2002;649-655
259. Faria T.N., LaRosa G.J., Wilen E., Liao J., Gudas L.J. Characterization of genes which exhibit reduced expression during the retinoic acid-induced differentiation of F9 teratocarcinoma cells: involvement of cyclin D3 in RA-mediated growth arrest. Mole Cell Endocrinol. 143:1998;155-166
260. Liu T., Malbon C.C., Wang H.Y., Lee Yn. Activation of the beta-catenin/Lef-Tcf pathway is obligate for formation of primitive endoderm by mouse F9 totipotent teratocarcinoma cells in response to retinoic acid. J Biol Chem. 277:2002;30887-30891
261. Lopatina N.G., Poole J.C., Saldanha S.N., et al. Control mechanisms in the regulation of telomerase reverse transcriptase expression in differentiation human teratocarcinoma cells. Biochem Biophys Res Commun. 306:2003;650-659
262. Frostesjo L., Holm I., Grahn B., Page A.W., Bestor T.H., Heby O. Interference with DNA methyltransferase activity and genome methylation during F9 teratocarcinoma stem cell differentiation induced by polyamine depletion. J Biol Chem. 272:1997;4359-4366
263. Trump D.L. Retinoids in bladder, testes and prostate cancer: epidemiologic, preclinical and clinical observations. Leukemia. 8(Suppl 3):1994;S50-S54
264. Yoskitake T., Itoyama S. Treatment of primary mediastinal germ cell tumors. Tinsho Kyobu Geka. 9:1989;29-34
265. Gerl A., Clemm C., Schmeller N., Hentrich M., Lamerz R., Wilmanns W. Late relapse of gem cell tumors after cisplatin-based chemotherapy. Ann Oncol. 8:1997;41-47
266. Chou T.C., Motzer R.J., Tong Y., Bosl G.J. Computerized quantitation of synergism and antagonism of tacol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 86:1994;1493-1495
267. Motzer RJ, Chou TC, Schwartz L, Bosl GJ, Bajorin DF, Hutter H. Paclitacel in germ cell cancer. Semin Oncol 1995; 22 (Suppl 6):12-5.
268. Iida K., Kawai K., Hayashi H., et al. Cases of refractory testicular cancer treated with all trans-retinoic acid. Gan To Kagaku Ryoho. 26:1999;841-844
269. Seeler J.S., Dehean A. The PML nuclear bodies: actors or extras? Curr Opin Genet Dev. 9:1999;362-367
270. Zhong S., Salomoni P., Pandolifi P.P. The transcriptional role of PML and the nuclear body. Nat Cell Biol. 2:2000;E85-E90
271. Pitha-Rowe I, Petty WJ, Kitareewan S, Dmitrovsky E. Retinoid target genes in acute promyelocytic leukemia. Leukemia 2003;17:1723-30.
272. Melnick A, Licht JD. Deconstruction a disease:RARα, its fusion partners, and their roles int the pathogenesis of acute promyelocytic leukemia. Blood 1999;99:3167-215.
273. Segalla S., Rinaldi L., Kilstrup-Nielsen C., et al. Retinoic acid receptor alpha fusion to PML affects in transcriptional and chromatin-remodeling properties. Mol Cell Biol. 23:2003;8795-8808
274. Alcalay M., Meani N., Gelmetti V., et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest. 112:2003;1751-1761
275. Dragnev K.H., Petty W.J., Dmitrovsky E. Retinoid targets in cancer therapy and chemoprevention. Cancer Biol Ther. 2(Suppl 1):2003;S150-S156
276. Warrell R.P. Jr., Frankel S.R., Miller W.H. Jr., Scheinberg D.A., Itri L.M., Hittelman W.N. Differention therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl J Med. 324:1991;1385-1393
277. Camacho L.H. Clinical application of retinoids in cancer medicine. J Biol Regul Homeost Agents. 17:2003;98-114
278. Ohno R., Asou N., Ohnishi K. Treatment of acute promyelocytic leukemia: stragegy toward further increase of cure rate. Leukemia. 17:2003;1454-1463
279. Parmar S., Tallman M.S. Acute promyelocytic leukaemia: a review. Expert Opin PHarmacother. 4:2003;1379-1392
280. Tallman M.S., Andersen J.W., Schiffer C.A., et al. All-transretinoic acid in acute romyelocytic leukemia: long-term outcome and prognostic factor analysis from North American Intergourp protocol Blood. 100:2002;4298-4302
281. Freemantle S.J., Spinella M.J., Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 22:2003;7305-7315
282. Gallagher R.E. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia. 16:2002;1940-1958
283. Marill J., Idres N., Capron C.C., Nguyen E., Chabot G.G. Retinoic acid metabolism and mechanism of action: a review. Curr Drug Metab. 4:2003;1-10
284. Mann K.K., Rephaeli A., Colosino Al, Diaz Z., Nudelman A., Levovich I. A retinoid/butyric acid produrg overcomes retinoic acid resistance in leukemias by induction of apoptosis. Mol Cancer Res. 1:2003;903-912
285. Fuchs E., Green H. Regulation of terminal differentiation of cultured heman keratinocytes by Vitamin A. Cell. 25:1981;617-625
286. Aneskievich B.J., Fuchs E. Terminal differentiation in deratinocytes involves positive as well as negative regulation by retinoic acid receptors and retinoid X receptors at retinoid response elements. Mole Cell Biol. 12:1992;4862-4871
287. De Luca L.M. Retinoids and their receptors in differentiation. FASEB J. 5:1991;2924-2933
288. Hong WK, Itri LM. Retinoids and human cancer. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids: biology, chemistry, and medicine. NY: Raven Press; 1994. p. 597-630.
289. Avvisati G., Tallman M.S. All-trans retinoic acid in acute promyelocytic leukemia. Best Pract Res Clin Haematol. 16:2003;419-432
290. Meyskens F.L. Jr., Salmon S.E. Inhibition of human melanoma colony formation by retinoids. Cancer Res. 39:1979;4055-4057
291. Meyskens F.L. Jr., Alberts E.X. Effect of 13-cis-retinoic acid and 4-hydroxyphenyl-all-trans-retinamide on human tumor colony formation in soft agar. Int J Cancer. 15:1983;295-299
292. Wan H, Hong WK, Lotan R. Increased retinoic acid responsiveness in lung carcinoma cells that are nonresponsive despite the presence of endogenous retinoic acid receptor (RAR) beta by expression of expgenous retinoid receptors retinoid X receptor α, RAR α, RAR-γ. Cancer Res. 2001;61:556-64.
293. Sun S.Y., Wan H., Yue P., Hong W.K., Lotan R. Evidence that retinoic acid receptor β induction by retinoids is important for tumor cell growth inhibition. J Biol Chem. 275:2000;17149-17153
294. Hong W.K., Lippman S., Itri L.M., et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 323:1990;795-801
295. Chen T.C., Holick M.F. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab. 14:2003;423-430
296. Galsky M., Kelly W.K. The development of differentiation agents for the treatment of prostate cancer. Semin Oncol. 30:2003;689-697
297. Reynolds C.P., Matthay K.K., Villablanca J.G., Maurer B.J. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 197:2003;185-192
298. Dalhoff K., Dancey J., Astrup L., et al. A phase II study of vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer. 89:2003;252-257
299. Manor D., Schmidt E.N., Budhu A., et al. Mammary carcinoma suppression by cellular retinoic acid binding protein-II. Cancer Res. 63:2003;4426-4433
300. Higughi E., Chandraratina R.A., Hong W.K., Lotan R. Induction of TGI3, a putative class II tumor sppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene. 22:2003;4627-4635
301. Shin DM, Khuri FR, Murphy B, et al. Combined interferon-α, 13-cis-retinoic acid, and α-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Cloin Oncol. 2001;19:3010-7.
302. Shin D.M., Glisson B.S., Khuri F.R., et al. Phase II and biologic study of interferon-α. Retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 20:2002;364-379
303. Camacho L.H. Clinical application of retinoids in cancer medicine. J Biol Regul Homeost Agents. 17:2003;98-114
304. Soria J.C., Xu X., Liu D.D., Lee J.J., et al. Retinic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst. 95:2003;165-168
305. Xu X.C., Lee J.S., Lee J.J., et al. Nuclear retinoid acid receptor-β in bronchial epithelium of smokers before and during chemoprevention. J Natl Cancer Inst. 91:1999;1317-1321
306. Kurie J.M., Lotan R., Lee J.J., et al. Treatment of former smokers with 9-cis-retinoic acid reverses loss of tetinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst. 95:2003;206-214
307. Meyskens F.L. Jr., Gilmartin E., Alberts D.S., et al. Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat Rep. 66:1982;1315-1319
308. Soria J.C., Kim E.S., Fayette J., Lantuejoul S., Deutsch E., Hong W.K. Chemoprevention of lung cancer. Lancet Oncol. 4:2003;659-669
309. Larson R.S., Tallman M.S. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol. 16:2003;453-461
310. Lanvers C., Reinhardt D., Dubbers A., et al. Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. Med Pediatr Oncol. 40:2003;293-301
311. Thrasher JD. Analysis of renewing epithelial cell populations. In: Prescott DM, editor. Methods in cell physiology, vol. 2. New York: Academic Press; 1966. p. 323-57.
312. Merock JR, Sherley JL. Breaching the kinetic barrisr to in vitro somatic stem cell propagation. J Biomed Biotechnol 2001;1:25-7.
313. Morin P.J., Sparks Korinek V., Barker N., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 275:1997;1787-1790
314. Marx J. Mutant stem cells may seed cancer. Science. 301:2003;1308-1310
315. Stocum DL. Stem Cells in Amphibian Regeneration. In: Sell S, editor. Stem cells handbook. Totowa, NJ: Humana Press; 2003. p. 89-100.
316. Sell S. Cellular origin of hepatocellular carcinomas. Cell Dev. Biol. 13:2002;419-424
317. Sell S. Immunology, immunopathology and immunity. 6th ed. Washington, DC: ASM Press; 2001. p. 26.
318. Sell S. Stem cells: What are they? Where do they come from, Why are they here? Where do they go wrong? Where are they going? In: Stem cells handbook. Totowa, NJ: Humana Press; 2003. p. 1-18.